In early stage studies, treatment with lenalidomide (Revlimid) has been associated with encouraging results among patients with relapsed and refractory chronic lymphocytic leukemia (CLL), with nearly 70% of patients responding to therapy. Lenalidomide is showing signs of altering the underlying disease state of CLL, further demonstrating the drug?s therapeutic potential across a broad group of hematological disorders and blood cancers.
Go to Previous Page
Go to Next Page